A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.
Key Details
- 1PRISM is the first major randomized U.S. trial to study AI in breast cancer screening.
- 2Supported by a $16 million award from PCORI, the study spans hundreds of thousands of mammograms across six states.
- 3Seven academic medical centers, including UCLA and University of Miami, are participating.
- 4The trial uses Transpara by ScreenPoint Medical as the AI tool, integrated via Aidoc aiOS.
- 5Radiologists will remain in control of interpretations, with randomized assignment to AI-assisted or radiologist-only reads.
- 6Outcomes include cancer detection, recall rates, and perceptions of AI from both patients and clinicians.
Why It Matters
This large, multicenter trial could establish high-level evidence on the true value of AI assistance in real-world breast imaging, directly influencing clinical implementation, policy, and practice. Its patient-centered design and rigorous methodology will help clarify how—and for whom—AI can best improve breast cancer screening results.
Source
EurekAlert
Related News
•EurekAlert
Osaka University Unveils Ultra-Fast Self-Evolving Edge AI for Real-Time Medical Devices
Osaka University researchers launch MicroAdapt, a revolutionary edge AI that brings ultra-fast, accurate real-time learning and forecasting to compact medical and industrial devices.
•EurekAlert
MAGIC AI System Enables High-Throughput Cancer Cell Imaging and Analysis
Researchers developed MAGIC, an AI-based system integrating automated microscopy and genomics to study chromosomal abnormalities linked to cancer.
•EurekAlert
Chinese Researchers Unveil Photonic Chip for Ultra-Fast Image Processing
A new photonic chip achieves image processing at 25 million frames per second with high energy efficiency, promising major advances in real-time imaging and AI applications.